Résultats de la recherche - Nikhil Yegya-Raman
- Résultat(s) 1 - 2 résultats de 2
-
1
Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot study par Abigail Berman, Andrea Facciabene, Nikhil Yegya-Raman, Francesca Costabile, Costantinos Koumenis, Kyle Bittinger, Ceylan Tanes, Nektarios Kostopoulos, Amit Maity, Edgar Ben-Josef, Shane Lloyd, Steven Joel Feigenberg, Roderick O’Connor, Divyansh Agarwal, Giorgos Skoufos, Silavano Salaris, Artemis Hatzigeorgiou, Cole Friedes, Lisha Chen, Keith Cengel, William Levin, Bakir Valentić, Tyler Quarton, Alexander A Shestov, Jeffrey Bradley
Publié 2025-07-01Background Gut microbiota modulation is an emerging strategy to improve cancer therapy outcomes. This study evaluated the safety and therapeutic potential of combining oral vancomycin—a non-absorbed, gut-restricted antibiotic with primary activity against gram-positive bacteria—with stereotactic bod...
Accéder au texte intégral
Article -
2
Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study par Nikhil Yegya-Raman, John P. Plastaras, Christopher M. Wright, Monica Chelius, Siqi Zhang, Jonathan A. Baron, Harper Hubbeling, Austin J. Sim, Timothy J. Robinson, Michael D. Jain, Brandon Imber, Beatrice Fregonese, Joachim Yahalom, Colton Ladbury, Savita Dandapani, Chelsea C. Pinnix, Jillian R. Gunther, Penny Q. Fang, Susan Y. Wu, Bouthaina S. Dabaja, Joanna C. Yang, Jessica Chew, Steve Braunstein, Sumi Sinha, Nathan M. Delinger, Susan Sun, Stephanie A. Terezakis, Gukan Sakthivel, Louis S. Constine, Amit K. Chowdhry, Patrick M. Reagan, Skyler Burke, Yolanda D. Tseng, Michael J. LaRiviere, Amit Maity, Stephen J. Schuster, Elise A. Chong, Nicholas B. Figura
Publié 2025-07-01Abstract: Despite the increasing utilization of bridging radiotherapy (Br-RT), its impact on chimeric antigen receptor T-cell therapy (CAR-T) efficacy and toxicity remains poorly characterized. We retrospectively reviewed patients with relapsed/refractory B-cell lymphomas (BCLs) who received Br-RT f...
Accéder au texte intégral
Article